NASDAQ · Biotechnology · USD
Lunai Bioworks Inc. (LNAI) Stock Analysis
Lunai Bioworks Inc. (LNAI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
LNAI Key Statistics
As of Sep 4, 2026Trading
- Open
- $2.31
- Previous Close
- $2.35
- Day's Range
- 2.30–2.40
- 52-Week Range
- 1.21–17.84
- Volume
- 12.50K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 0.34
Valuation
- Market Cap
- $10.84M
- P/E Ratio
- unprofitable
- P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
- 517.43
- EPS (ttm)Profit attributable to each share over the last twelve months.
- −62.83
Financials (FY)
- Revenue (FY)
- $0.00
- Net Income (FY)
- −$178.01M
- Profit marginThe share of revenue left as profit after all costs and taxes.
- 0.00%
- Shares Outstanding
- 4.53M
- 1-Year Return
- −85.97%
Dividend and dates
- Earnings Date
- September 28, 2026estimated
- Avg Volume
- 970.89K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
LNAI Stock Return by Calendar Year
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | −66.13% |
| 2025 | −89.45% |
| 2024 | −73.63% |
| 2023 | +207.77% |
| 2022 | −85.87% |
| 2021 | +147.12% |
| 2020 | −41.24% |
| 2019 | −28.29% |
| 2018 (partial year) | +18.64% |
As of September 4, 2026.
LNAI Revenue and Earnings by Fiscal Year
FY ends June| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $0.00 | −$178.01M | — |
| 2024 | $0.00 | −$88.43M | — |
| 2023 | $0.00 | −$39.68M | — |
| 2022 | $0.00 | −$113.43M | — |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $0.00 | — | −$18.55M | −$178.01M | — |
| 2024 | $0.00 | $0.00 | −$27.39M | −$88.43M | — |
| 2023 | $0.00 | $0.00 | −$19.60M | −$39.68M | — |
| 2022 | $0.00 | — | −$22.83M | −$113.43M | — |
Annual figures as reported, in the company's reporting currency. As of June 30, 2025.
LNAI Valuation vs Biotechnology Median
Median of 656 stocks| Metric | LNAI | Biotechnology median | vs median |
|---|---|---|---|
| P/S ratio | 517.43 | 15.26 | 33.9x the median |
| Profit margin | 0.00% | 0.00% | 0.0 pts above |
Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.
Recent News
Lunai Bioworks Files Second Amended Complaint Against Six Registered Broker-Dealers And Two Broker-Dealer Principals As Defendants In U.S. District Court, Delaware
BenzingaLunai Bioworks Signs Master Collaboration Agreement With BrainStorm Therapeutics; BioSymetrics Publishes Parkinson's Disease AI White Paper, Initial Data Expected In 1H 2027
BenzingaLunai Bioworks Files Amended RICO Complaint Expanding Naked Short-Selling Lawsuit; Names 10 Defendants, Including 3 FINRA Registered Broker Dealers, In Connection With An Alleged Coordinated Naked Short Selling Scheme That The Company Says Generated Failures To Deliver On More Than 81% Of Its Outstanding Shares
Benzinga
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$138.42B
REGNRegeneron Pharmaceuticals, Inc.
$85.22B
ARGXargenx SE
$64.25B
MRNAModerna, Inc.
$58.11B
RVMDRevolution Medicines, Inc.
$45.01B
ONCBeOne Medicines AG
$40.53B
Popular Healthcare Stocks
Eli Lilly and Company
$1.02T
JNJJohnson & Johnson
$663.28B
ABBVAbbVie Inc.
$453.19B
MRKMerck & Co., Inc.
$370.89B
UNHUnitedHealth Group Incorporated
$356.47B